MKS St. Paulus GmbH
- Address
- Goethestrasse 19, 58239 Schwerte, Germany
MKS St. Paulus GmbH - Breast Cancer Research Center
MKS St. Paulus GmbH is a specialized clinical research facility dedicated to advancing breast cancer treatment through participation in innovative Phase II and III clinical trials. The center focuses on personalized, marker-adjusted therapeutic approaches across multiple breast cancer subtypes, with particular expertise in neoadjuvant and adjuvant treatment strategies.
- Triple-negative breast cancer (TNBC) with novel antibody-drug conjugates and immunotherapy combinations
- HER2-positive early breast cancer investigating next-generation targeted therapies including trastuzumab-deruxtecan
- HR+/HER2- early breast cancer with CDK4/6 inhibitor-based personalized treatment approaches
- Age-specific breast cancer management in older patient populations as alternatives to chemotherapy
The center's research portfolio emphasizes dynamic marker-adjusted personalized therapy (ADAPT) protocols, evaluating innovative combinations of endocrine therapy with targeted agents such as abemaciclib, ribociclib, and palbociclib. Their trials aim to identify patient populations who can achieve superior outcomes while potentially avoiding conventional chemotherapy, with a focus on optimizing pathologic complete response rates, invasive disease-free survival, and long-term distant disease-free survival across risk-stratified breast cancer cohorts.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 1 therapeutic areas and 15 of 18 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 3 by active trials.
lock +2 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 2 161 other sites in Germany
Therapeutic Area Benchmark — Germany
Select a therapeutic area to compare against other sites in Germany.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Germany
Market Share
Country: Germany
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in MKS St. Paulus GmbH
lock Showing 1 of 10 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| Adjuvant Dynamic Marker-Adjusted Personalized Therapy: Ribociclib Plus Endocrine Therapy Versus Chemotherapy in HR+/HER2- Early Breast Cancer | WSG Westdeutsche Studiengruppe GmbH | Phase III | Not Recruiting | Jul 2019 | — |
IMP list
lock Showing 1 of 18 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Trastuzumab Deruxtecan | 3 | Unknown | 2024-02-05 | 2026-02-18 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.